ILX 295501
Alternative Names: LY 295501Latest Information Update: 24 Oct 2021
At a glance
- Originator Eli Lilly and Company
- Developer Genzyme Oncology
- Class Antineoplastics; Small molecules; Sulfonylureas
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Renal cancer
Most Recent Events
- 18 Sep 2018 Genzyme withdraws a phase II trial for Ovarian cancer and Fallopian-tube-cancer (Late stage disease, Metastatic disease, Second line therapy or greater) prior to enrolment in the USA (NCT00005645)
- 29 Dec 2004 ILEX Oncology has been acquired by Genzyme Corporation
- 27 May 2004 A clinical study has been added to the pharmacokinetics section